F. de Braud

发表

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

C. Bokemeyer, I. Bondarenko, I. Çelik, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

R. Labianca, C. Boni, A. Zaniboni, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.

V. Torri, M. Garassino, F. Pietrantonio, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination

D. Radice, C. Boni, T. De Pas, 2011, Chemotherapy.

Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.

S. Zambito, G. Curigliano, T. De Pas, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Gemcitabine-induced systemic capillary leak syndrome.

L. Spaggiari, G. Curigliano, F. de Braud, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

G. Giaccone, S. Bates, M. Atkins, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.

C. Boni, G. Curigliano, O. Pagani, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?

A. Goldhirsch, M. Aapro, N. Fazio, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.

R. Stupp, R. Herrmann, A. Goldhirsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study.

V. Adamo, L. Rimassa, A. Zaniboni, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.

G. Curigliano, R. Danesi, S. Fogli, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

H. Joensuu, P. Casali, C. Spreafico, 2011, British Journal of Cancer.

Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

H. Joensuu, P. Casali, C. Spreafico, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

G. Jayson, M. Sawyer, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

M. Gariboldi, F. Perrone, A. Busico, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.

J. Berlin, M. Thomas, A. Santoro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.

A. Goldhirsch, M. Aapro, S. Monti, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III.

R. Labianca, M. Ducreux, A. Zaniboni, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).

A. Goldhirsch, U. Veronesi, G. Martinelli, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

M. Ducreux, P. Soulié, M. Marty, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

A. de Gramont, C. Louvet, N. Le bail, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials.

S. Cascinu, P. Conte, D. Neri, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.